We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

KineMed Collaborates with Forbes Medi-Tech

KineMed Collaborates with Forbes Medi-Tech

KineMed Collaborates with Forbes Medi-Tech

KineMed Collaborates with Forbes Medi-Tech

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KineMed Collaborates with Forbes Medi-Tech "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KineMed, Inc. has announced that it has signed an exclusive agreement with Forbes Medi-Tech Inc. to discover non-cardiovascular indications for an undisclosed compound in the Forbes library of small molecule compounds.

Under the terms of the agreement, KineMed will screen the Forbes compound using KineMed's proprietary in vivo KineMarker™ assays.

KineMed and Forbes will have the option to pursue development of the compound in any discovered indications.

"We are excited to collaborate with Forbes and expect to begin evaluating additional therapeutic activity this quarter," said David Fineman, President and CEO of KineMed.

"Our goal is to identify potential applications that can address large markets with substantial unmet medical needs."

"This collaboration represents KineMed's continued progress in the application of our KineMarker platform to new indications discovery."